{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aggressive+Therapy",
    "query": {
      "intervention": "Aggressive Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 330,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aggressive+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T02:32:03.246Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03132584",
      "title": "Cyclophosphamide and Alemtuzumab In Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2017-07-30",
      "completion_date": "2018-01-30",
      "has_results": false,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132584"
    },
    {
      "nct_id": "NCT03695120",
      "title": "RAAS Optimization for Acute CHF Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Decompensated Heart Failure"
      ],
      "interventions": [
        {
          "name": "Change of treatment plan",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-02-08",
      "completion_date": "2021-04-12",
      "has_results": false,
      "last_update_posted_date": "2021-04-22",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695120"
    },
    {
      "nct_id": "NCT00184002",
      "title": "Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2003-01-10",
      "completion_date": "2013-05-07",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00184002"
    },
    {
      "nct_id": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CHOP regimen",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "19 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-09-01",
      "completion_date": "2003-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Omaha, Nebraska",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004112"
    },
    {
      "nct_id": "NCT04654260",
      "title": "Behavior Therapy for Irritability in Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Irritability",
        "Disruptive Behavior",
        "Anger",
        "Aggression",
        "Asperger Syndrome",
        "Pervasive Developmental Disorder"
      ],
      "interventions": [
        {
          "name": "Behavioral Therapy for Irritability in Autism",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Psychoeducation and Supportive Therapy (PST)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "12 Years to 19 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-12-10",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04654260"
    },
    {
      "nct_id": "NCT01735630",
      "title": "Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ELND005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 350,
      "start_date": "2012-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735630"
    },
    {
      "nct_id": "NCT01434472",
      "title": "High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Indium In-111 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Yttrium Y-90 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-11-16",
      "completion_date": "2020-05-06",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434472"
    },
    {
      "nct_id": "NCT00486551",
      "title": "Anger Control Training for Youth With Tourette Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tourette Syndrome",
        "Chronic Tic Disorder",
        "Oppositional Defiant Disorder",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Anger control training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "11 Years to 16 Years"
      },
      "enrollment_count": 26,
      "start_date": "2001-08",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2022-02-11",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486551"
    },
    {
      "nct_id": "NCT00718770",
      "title": "A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Bexarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2008-11",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00718770"
    },
    {
      "nct_id": "NCT05657860",
      "title": "Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prader-Willi Syndrome",
        "Aggression",
        "Self-Injurious Behavior",
        "Pathologic Processes",
        "Behavioral Symptoms",
        "Intellectual Disability",
        "Neurobehavioral Manifestations",
        "Neurologic Manifestations",
        "Nervous System Diseases",
        "Abnormalities, Multiple",
        "Congenital Abnormalities",
        "Chromosome Disorders",
        "Genetic Diseases, Inborn",
        "Obesity",
        "Overnutrition",
        "Nutrition Disorders",
        "Antihypertensive Agents",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action",
        "Physiological Effects of Drugs",
        "Skin-Picking"
      ],
      "interventions": [
        {
          "name": "Guanfacine Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Maimonides Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-17",
      "completion_date": "2023-12-16",
      "has_results": false,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-09-12T02:32:03.246Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05657860"
    }
  ]
}